Completed PHASE3 INTERVENTIONAL 2-arm NCT03296163

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Sponsor: mAbxience Research S.L.

Conditions Non-small Cell Lung Cancer

Interventions Carboplatin EU-approved Avastin® MB02 (Bevacizumab Biosimilar Drug) Paclitaxel

Updated 20 times since 2017 Last updated: Mar 26, 2021 Started: Feb 6, 2018 Primary completion: Jul 3, 2019 Completion: Feb 27, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non-small Cell Lung Cancer and is currently completed. mAbxience Research S.L. leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3

▶ Show 15 earlier versions

Oct 2022 — Dec 2022 [monthly]

Completed PHASE3
May 2021 — Oct 2022 [monthly]

Completed PHASE3
Apr 2021 — May 2021 [monthly]

Completed PHASE3
Jan 2021 — Apr 2021 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Apr 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE3
Dec 2018 — Feb 2019 [monthly]

Recruiting PHASE3
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Mar 2018 [monthly]

Not Yet Recruiting PHASE3
Oct 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

mAbxience Research S.L.

Data source: mAbxience Research S.L.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Arkhangelsk, Russia , Athens, Greece , Baguio City, Philippines , Bangkok, Thailand , Barretos, Brazil , Batumi, Georgia , Belgorod, Russia , Belgrade, Serbia , Budapest, Hungary and 84 more locations